ACS 患者 PCI 围术期心梗的演变定义预后比较
本研究基于 MATRIX 试验,纳入 6724 例行 PCI 的 ACS 患者,前瞻性比较第二、第三与第四版全球心梗定义对 PCI-MI 的判定率及其与 1 年死亡风险的关系。结果显示,仅第四版定义下的 PCI-MI 在非 ST 段抬高 ACS 患者中与全因死亡(HR 2.08,95% CI 1.00–4.30)和心血管死亡(HR 2.62,95% CI 1.03–6.65)风险增加显著相关。在无客观辅助证据时,即使肌钙蛋白升高至正常上限的 20 倍,也不增加死亡风险。
要点
- 在 NSTE-ACS 患者中,仅按第四版定义判定的 PCI-MI 与 1 年死亡风险增加显著相关。
- 在 STEMI 患者中,PCI-MI 发生率较低(1%–4%),且与死亡风险增加无关。
- 若无心电图或造影并发症等客观证据,单纯肌钙蛋白升高(≤20 倍上限)不增加死亡风险。
核心结论
- 按第四版全球心梗定义判定的 PCI-MI 仅在非 ST 段抬高 ACS 患者中与 1 年全因死亡和心血管死亡风险增加显著相关,支持该定义的演变。
研究设计与样本
- 基于 MATRIX 试验(NCT01433627)的前瞻性队列研究,纳入 6724 例行 PCI 的 ACS 患者。
- 分别依据第二、第三及第四版全球心梗定义前瞻性判定 PCI-MI 事件。
- 主要终点为非 ST 段抬高 ACS 患者在 PCI 后 24 小时至 1 年的全因死亡和心血管死亡。
主要发现
- 在整个 ACS 人群中,PCI-MI 发生率按第二版为 9%(590 例)、第三版为 3%(193 例)、第四版为 3%(182 例)。
- 在 NSTE-ACS 中,各版定义的 PCI-MI 发生率分别为 15%、5% 和 5%。
- 仅第四版定义判定 PCI-MI 的 NSTE-ACS 患者全因死亡风险显著升高(HR 2.08,95%CI 1.00–4.30,P=0.048)。
- 该人群心血管死亡风险亦显著升高(HR 2.62,95%CI 1.03–6.65,P=0.043)。
- 在 STEMI 患者中,PCI-MI 发生率在 1% 至 4% 之间,且与死亡风险增加无关联。
关键数值与推荐
- 无客观辅助标准(心电图、造影并发症)时,单纯肌钙蛋白升高不超过正常上限 20 倍不增加死亡风险。
临床怎么用
- 临床可优先采用第四版全球心梗定义判定 NSTE-ACS 患者的 PCI 相关心梗。
- 对 PCI 术后肌钙蛋白升高但无心电图或造影异常者,不应过度解读为高风险 PCI-MI。
局限性
- 研究人群为 MATRIX 试验中的 ACS 患者,外推至其他人群需谨慎。
- PCI-MI 事件的判定依赖于试验中前瞻设定的裁定流程。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The universal definition of percutaneous coronary intervention (PCI)-related myocardial infarction (MI) has been substantially updated over the years, including an increase in the biomarker threshold (from 3 to 5 times the upper reference limit) and the introduction of ancillary criteria such as ischemic symptoms and electrocardiographic or angiographic complication. The impact of these changes in patients with acute coronary syndrome (ACS) remains incompletely understood. The objective of this study was to compare prognostic implications of evolving universal definitions of PCI-MI in a large cohort of patients with ACS from the MATRIX trial (Minimizing Adverse Haemorrhagic Events by Transradial Access Site and Systemic Implementation of AngioX). METHODS: Among 6724 patients undergoing PCI in the MATRIX trial, PCI-MI was prospectively adjudicated by the second, third and fourth universal definition of MI (UDMI). The 2 co-primary end points were all-cause and cardiovascular death (from 24 hours to 1 year after PCI) in patients with non-ST-segment-elevation ACS. Hazard ratios and 95% CIs were generated for primary and secondary end points with the use of Cox proportional hazards time-to-event analyses for each MI definition. RESULTS: PCI-MI occurred in 590 patients (9%) with the second UDMI, 193 (3%) with the third UDMI, and 182 (3%) with the fourth UDMI applied in the overall ACS population. Among patients with non-ST-segment-elevation ACS, the corresponding figures were 15%, 5%, and 5%. Only PCI-MI defined by the fourth UDMI in patients with non-ST-segment-elevation ACS was associated with increased risks of all-cause (hazard ratio, 2.08 [95% CI, 1.00-4.30]; P=0.048) and cardiovascular (hazard ratio, 2.62 [95% CI, 1.03-6.65]; P=0.043) death. In patients with ST-segment-elevation myocardial infarction, PCI-MI was uncommon (1% to 4% depending on the working definition) and was not associated with increased mortality. In the absence of objective ancillary criteria (electrocardiographic and angiographic complications), isolated troponin elevations up to 20 times the upper reference limit were not associated with increased mortality risk. CONCLUSIONS: PCI-MI defined according to the fourth UDMI was associated with increased risks of 1-year mortality only in patients with non-ST-segment-elevation ACS. These data support the evolution of the universal definition of PCI-MI. REGISTRATION: URL: http://www.clinicaltrials.gov; Unique identifier: NCT01433627.
引用
- Leonardi, Landi, Zito, et al. Prognostic Implications of Evolving Universal Definitions of Periprocedural Myocardial Infarction in Patients With Acute Coronary Syndrome. Circulation. 2026. PMID: 41493005. doi:10.1161/CIRCULATIONAHA.125.077174
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。